Abstract
Background. Platelets (plt) prepared for transfusion contain multiple molecules that modulate immune function, mediate acute transfusion reactions, induce immune responses, and affect hemostasis. These cytokines/chemokines are secreted differentially from plt during storage (
Aims. The INTERCEPT Blood System (IBS) for platelets utilizes amotosalen-HCl (S-59) with ultraviolet A (UVA) light to inactivate a broad spectrum of pathogens and leukocytes. This study was designed to evaluate the effects of photochemical treatment on in vitro release of immune modulation molecules after processing during 7 days (d) of storage.
Methods. Platelet concentrates (n = 10) collected by aphaeresis (CPA) with process leuko-reduction (< 106) containing 8.15x1011 ± 0.8 platelets were suspended in 35% donor plasma and 65% platelet additive solution (Intersol, Baxter, France) and divided into two equal components. One served as an untreated control (C) and the other was prepared with 150 uM amotosalen and a 3 J/cm2 UVA photochemical treatment (PCT) and stored at 22°C with shaking for 7 days. Platelet concentration (106/uL), pH and levels of immune modulation factors were measured: CD62p(ng/mL), PDGF-AB(ng/mL), IL8(pg/mL), sCD40L(pg/mL), IL1β(pg/mL) and TNFα(pg/mL). The concentration of each factor was determined by specific enzyme linked immunosorbent assays in plt and supernatant (s) fractions isolated from stored PCT and C plt components. Mean values ± SD were calculated and compared by paired t-test.
Results. Platelet content, pH and cytokine/chemokine content and release from CPA prepared with photochemical treatment were not statistically different (p > 0.05) from C during 7 d of storage (Table). From d1 to d7, the pH of PCT and C units decreased similarly, but remained within acceptable ranges. No detectable IL1β and TNFα were observed in PCT or C CPA. During platelet storage CD62p, PDGF-AB, IL8, and sCD40L increased similarly in supernatants of PCT and C units. The increase in supernatant levels correlated with a decrease of these cytokines in plt. Platelets in PCT and C retained measurable levels of CD62, IL8, sCD40L and PDGF-AB though 7 d. Levels of sCD40L demonstrated marked variation.
Conclusions. Cytokines increased moderately in the supernatants of CPA and decreased in platelets during storage. After 7 d C and PCT platelets in CPA retained detectable levels of cytokines. PCT had no differential influence on release of immune modulation molecules in vitro over 7 d of storage.
Day . | O . | O . | 5 . | 5 . | 7 . | 7 . |
---|---|---|---|---|---|---|
Product | C | PCT | C | PCT | C | PCT |
pH | 7.1 ±.1 | 7.1 ±.1 | 6.9 ±.1 | 6.8 ±.1 | 6.9 ±.1 | 6.8 ±.1 |
Plt ct | 1.29 ±.3 | 1.30 ±.2 | 1.30 ±.3 | 1.19 ±.2 | 1.27 ±.2 | 1.18 ±.2 |
CD62p-s | 89 ± 21 | 87 ± 17 | 110 ± 23 | 115 ± 27 | 117 ± 22 | 119 ± 25 |
CD62p-plt | 149 ± 33 | 151 ± 33 | 141 ± 23 | 141 ± 25 | 139 ± 25 | 139 ± 26 |
PDGF-s | 14.5 ± 3.5 | 13.6 ± 3.5 | 17.7 ± 2.4 | 15.8 ± 1.5 | 18.0 ± 2.1 | 17.5 ± 1.8 |
PDGF-plt | 28.3 ± 3.5 | 30.3 ± 3.1 | 25.2 ± 3.6 | 24.9 ± 2.5 | 23.2 ± 4.0 | 23.3 ± 3.3 |
IL8-s | 107 ± 17 | 108 ± 14 | 136 ± 42 | 116 ± 9 | 123 ± 20 | 120 ± 22 |
IL8-plt | 135 ± 29 | 134 ± 28 | 110 ± 11 | 117 ± 12 | 103 ± 17 | 119 ± 32 |
CD40L-s | 51 ± 86 | 66 ± 94 | 172 ± 157 | 237 ± 214 | 188 ± 198 | 201 ± 167 |
CD40L-plt | 990 ± 805 | 1098 ± 747 | 485 ± 373 | 474 ± 331 | 346 ± 293 | 314 ± 282 |
Day . | O . | O . | 5 . | 5 . | 7 . | 7 . |
---|---|---|---|---|---|---|
Product | C | PCT | C | PCT | C | PCT |
pH | 7.1 ±.1 | 7.1 ±.1 | 6.9 ±.1 | 6.8 ±.1 | 6.9 ±.1 | 6.8 ±.1 |
Plt ct | 1.29 ±.3 | 1.30 ±.2 | 1.30 ±.3 | 1.19 ±.2 | 1.27 ±.2 | 1.18 ±.2 |
CD62p-s | 89 ± 21 | 87 ± 17 | 110 ± 23 | 115 ± 27 | 117 ± 22 | 119 ± 25 |
CD62p-plt | 149 ± 33 | 151 ± 33 | 141 ± 23 | 141 ± 25 | 139 ± 25 | 139 ± 26 |
PDGF-s | 14.5 ± 3.5 | 13.6 ± 3.5 | 17.7 ± 2.4 | 15.8 ± 1.5 | 18.0 ± 2.1 | 17.5 ± 1.8 |
PDGF-plt | 28.3 ± 3.5 | 30.3 ± 3.1 | 25.2 ± 3.6 | 24.9 ± 2.5 | 23.2 ± 4.0 | 23.3 ± 3.3 |
IL8-s | 107 ± 17 | 108 ± 14 | 136 ± 42 | 116 ± 9 | 123 ± 20 | 120 ± 22 |
IL8-plt | 135 ± 29 | 134 ± 28 | 110 ± 11 | 117 ± 12 | 103 ± 17 | 119 ± 32 |
CD40L-s | 51 ± 86 | 66 ± 94 | 172 ± 157 | 237 ± 214 | 188 ± 198 | 201 ± 167 |
CD40L-plt | 990 ± 805 | 1098 ± 747 | 485 ± 373 | 474 ± 331 | 346 ± 293 | 314 ± 282 |
Disclosures: Laurence Corash is an employee of Cerus Corp.; Laurence Corash owns stock and stock options in Cerus Corp.; Olivier Garraud and Jean Claude Osselaer received research funding for this study.; Olivier Garraud and Jean Claude Osselaer serve on the Cerus European Advisory Board.
Author notes
Corresponding author